Gateway Investment Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Gateway Investment Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$204K	Buy	+1,208	New	+$179K	﹤0.01%	774

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Gateway Investment Advisers's NBIX Position: Q2 2026 in Review

Gateway Investment Advisers opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,208 shares worth $204K. The stake represents ﹤0.01% of the portfolio and ranks #774 among its holdings.

166 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Gateway Investment Advisers held 1,208 shares of Neurocrine Biosciences worth $204K as of Q2 2026.
Neurocrine Biosciences was a new Gateway Investment Advisers position in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Gateway Investment Advisers's portfolio in Q2 2026, its #774 holding.
166 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Gateway Investment Advisers's 13F filing for Q2 2026, filed 20 Jul 2026.